Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Yu Sawada(Yokohama City University), Tetsuya Nakatsura(Unknown), Katsuhiko Uesaka(Shizuoka Cancer Center), Masafumi Ikeda(National Cancer Center Hospital East), Nobuhiro Tsuchiya(Yokohama City University), Shoichi Mizuno(Shizuoka Cancer Center), Kohei Nakachi(National Cancer Center Hospital East), Itaru Endo(Yokohama City University), Toshiaki Yoshikawa(Aichi Cancer Center), Naoto Gotohda(Shizuoka Cancer Center), Daisuke Nobuoka(Fukuyama City Hospital), Junji Furuse(Kanagawa Prefectural Hospital Organization), Masaru Konishi(Shizuoka Cancer Center), Kenji Yamao(Aichi Cancer Center), Kazuya Ofuji(Chiba Cancer Center), Shinichiro Takahashi(Shizuoka Cancer Center), Tadatoshi Takayama(Nihon University), Yuichiro Kato(National Cancer Center Hospital East), Mayuko Yoshimura(Chiba Cancer Center), Naoya Yamazaki(Tokyo National Hospital), Taira Kinoshitá(National Cancer Center Hospital East), Mari Takahashi(Chiba Cancer Center)
Cited by 178
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977